Drug Approval | December 05, 2025
Lupin receives FDA’s tentative approval for Siponimod tablets
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Subscribe To Our Newsletter & Stay Updated
